WaveMan
WaveMan · Company
MIST · Milestone Pharmaceuticals Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MIST Milestone Pharmaceuticals (MIST) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001408443
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
30
13F, latest reported quarter

Milestone Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Milestone Pharmaceuticals Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Oliveto Joseph
President and CEO
SELL
2026-04-20 SECtraded 2026-04-16
36,500
$82.5K
-66.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jan 26, 2026.
  • The trade is 8.2% of the 446,244 shares held after it.
  • No other insider sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Oliveto Joseph sold about $82.5K of MIST on Apr 16, 2026; 30 funds added in the latest 13F quarter.
Bharucha David
Chief Medical Officer
SELL
2026-01-28 SECtraded 2026-01-26
12,245
$23.6K
-65.9%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Dec 15, 2025.
  • -30.0% median (-30.0% mean) 90-day return after 2 previous buys.
  • The trade is 10.8% of the 113,181 shares held after it.
  • 4 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Bharucha David sold about $23.6K of MIST on Jan 26, 2026; 4 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
Nelson Jeffrey Edward
Chief Operating Officer
SELL
2026-01-28 SECtraded 2026-01-26
12,245
$23.6K
-65.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 15, 2025.
  • The trade is 24.6% of the 49,848 shares held after it.
  • 4 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Nelson Jeffrey Edward sold about $23.6K of MIST on Jan 26, 2026; 4 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
Muller Lorenz
Chief Commercial Officer
SELL
2026-01-28 SECtraded 2026-01-26
11,180
$21.6K
-65.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 15, 2025.
  • The trade is 5.4% of the 205,406 shares held after it.
  • 4 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Muller Lorenz sold about $21.6K of MIST on Jan 26, 2026; 4 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
Hasija Amit
CFO & EVP of Corp. Development
SELL
2026-01-28 SECtraded 2026-01-26
12,245
$23.6K
-65.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 15, 2025.
  • The trade is 12.3% of the 99,848 shares held after it.
  • 4 other insiders sold within 30 days.
  • 30 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO & EVP of Corp. Development Hasija Amit sold about $23.6K of MIST on Jan 26, 2026; 4 other insiders sold within 30 days and 30 funds added in the latest 13F quarter.
23 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 18 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
30 funds bought in last quarter
below 62% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
-5118.8% net margin (latest quarter)
below 98% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
18.5% of the float short (float per yahoo 2026-10-27) · 18.7 days to cover · settled 2026-10-15
more than 87% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch MIST

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-65.9%12M
-66%-25%+15%+56%2025-102025-122026-022026-042026-062026-082026-10 2025-12-15 · Oliveto Joseph sold $308.7K2025-12-15 · Bharucha David sold $134.6K2025-12-15 · Nelson Jeffrey Edward sold $134.6K2025-12-15 · Hasija Amit sold $134.6K2025-12-15 · Muller Lorenz sold $124.3K2026-01-08 · Oliveto Joseph sold $96.8K2026-04-16 · Oliveto Joseph sold $82.5K2026-01-26 · Oliveto Joseph sold $66.6K2026-01-26 · Bharucha David sold $23.6K2026-01-26 · Nelson Jeffrey Edward sold $23.6K2026-01-26 · Hasija Amit sold $23.6K2026-01-26 · Muller Lorenz sold $21.6K2026-01-07 · Oliveto Joseph sold $1.1K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MIST: institutional holders (13F)

13F holdings, latest reported quarter
Pavaki Capital Management LLC
9,067,848 sh
$12.2M
RTW INVESTMENTS, LP
7,833,336 sh
$10.5M
Propel Bio Management, LLC
7,429,590 sh
$10.0M
Point72 Asset Management, L.P.
5,411,138 sh
$7.3M
Simplify Asset Management Inc.
3,349,379 sh
$4.5M

Congress trades in MIST

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MIST planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

MIST mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Propel Opportunities ETF
$4.5M position · as of 2026-06-30
5.8%
Invesco NASDAQ Future Gen 200 ETF
$63.8K position · as of 2026-05-31
0.3%
State Street(R) SPDR(R) S&P(R) International Small Cap ETF
$30.2K position · as of 2026-06-30
0.0%
Blackstone Alternative Multi-Strategy Fund
$14.7K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$57.9K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 30 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MIST financials

Net margin
-5118.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$61.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
3.25x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-1.04x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-8,886%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-18.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-79.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
-$30.3M
market value at close 2026-10-26 on 2026-08-12 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-76.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$62.1M-$42.1M-$61.1M-$59.6M
Net income-$63.1K-$41.5K-$59.7K-$58.4M
EPS (diluted)-0.75-0.67-1.39-1.38
Operating cash flow-$49.0M-$28.8M-$46.4M-$52.5M
Cash$73.0M$25.3M$13.8M$7.6M
Long-term debt$57.2M$53.4M$49.8Mn/a
SEC XBRL, fiscal years, as known on 2026-10-28

MIST Stock Sonar score 4/7 axes

Find similar shapesCompare

MIST ranks highest on institutional and government (38th percentile) and profitability (34th), and lowest on risk and compliance (27th), among Pharma & Biotech peers.

Profitability
34
Inputs
  • Return on equity-8886% · 1 pct, sector of 545
  • Return on assets-18.4% · 68 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-79.3% · 33 pct, sector of 576
Financial health
28
Inputs
  • Debt to equity3.25x · 5 pct, sector of 352
  • Cash flow to debt-1.04x · 51 pct, sector of 371
Institutional and government
38
Inputs
  • Funds adding, latest quarter30 · 38 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
27
Inputs
  • Short interest, % of float+17.9% · 19 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+13.6% · 35 pct, sector of 511
3 not measured: Growth, Insider conviction, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies